The UK and US have signed a landmark bilateral deal that will keep no import taxes on British pharmaceutical shipments being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost expenditure on drugs through the NHS. This move ensures that tariffs on these crucial products will stay at nothing for a period of 36 months.
This development follows earlier statements to dramatically increase tariffs on patented drug products, with potential rates discussed as high as one hundred percent.
"This agreement between the United Kingdom strengthens the worldwide climate for new treatments and establishes much-needed equity to transatlantic pharmaceutical trade," a statement declared.
Trade Impact
Drugs are one of the UK's largest goods shipped to the America, which is easily the primary buyer for major companies like GSK and AstraZeneca.
Statistics show that in the 12 months prior to September, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This value made up 17.4% of British export trade in that span.
"This deal secures jobs, stimulates capital expenditure and paves the way for the UK to become a worldwide center for life sciences," the Business and Trade Secretary commented.
Specific NHS Changes
The pact includes several specific commitments from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a target to double overall public funding on medicines from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must refund to the NHS to control costs will be limited at 15%. Previously, repayments were more than 20%.
Broader Context
This agreement follows a ongoing row between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
The disagreement were heightened by claims that American consumers were charged several times more for the identical medicines than patients in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been paused or scrapped, while major investments have been directed toward American operations.
The Science Minister publicly accepted that the NHS had to spend more on medicines, noting that its expenditure on drugs had declined as a proportion of its resources over the past decade.
